Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEF Therapy in Late-stage NSCLC
NCT05987345Recruiting
- Sponsor
- Energenx Medical Ltd.
- Start
- Jul 2023
- Primary completion
- Jul 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial, sponsored by Energenx Medical Ltd. Primary endpoints: Technical success rate of PEF treatment at 7 days and Incidence of PEF treatment related AE/SAEs at 1 month. Started Jul 2023; status: recruiting.
Beyond the preview
Go deeper on NCT05987345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05987345.